| Pan-KRAS inhibitor disables oncogenic signalling and tumour growth D Kim, L Herdeis, D Rudolph, Y Zhao, J Böttcher, A Vides, ... Nature 619 (7968), 160-166, 2023 | 91 | 2023 |
| RIT1 oncoproteins escape LZTR1-mediated proteolysis P Castel, A Cheng, A Cuevas-Navarro, DB Everman, AG Papageorge, ... Science 363 (6432), 1226-1230, 2019 | 79 | 2019 |
| Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination JH Wald, J Hatakeyama, I Printsev, A Cuevas, WHD Fry, MJ Saldana, ... Oncogene 36 (36), 5158-5167, 2017 | 50 | 2017 |
| Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS CJ Schulze, KJ Seamon, Y Zhao, YC Yang, J Cregg, D Kim, A Tomlinson, ... Science 381 (6659), 794-799, 2023 | 29 | 2023 |
| RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity P Castel, S Dharmaiah, MJ Sale, S Messing, G Rizzuto, ... Proceedings of the National Academy of Sciences 118 (33), e2103261118, 2021 | 27 | 2021 |
| The RAS GTPase RIT1 compromises mitotic fidelity through spindle assembly checkpoint suppression A Cuevas-Navarro, R Van, A Cheng, A Urisman, P Castel, F McCormick Current Biology 31 (17), 3915-3924. e9, 2021 | 17 | 2021 |
| Impaired proteolysis of noncanonical RAS proteins drives clonal hematopoietic transformation S Chen, RS Vedula, A Cuevas-Navarro, B Lu, SJ Hogg, E Wang, ... Cancer discovery 12 (10), 2434-2453, 2022 | 16 | 2022 |
| The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3 J Hatakeyama, JH Wald, H Rafidi, A Cuevas, C Sweeney, KL Carraway III Science signaling 9 (434), ra65-ra65, 2016 | 15 | 2016 |
| Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs A Cuevas-Navarro, L Rodriguez-Muñoz, J Grego-Bessa, A Cheng, ... Elife 11, e76495, 2022 | 14 | 2022 |
| The molecular functions of RIT1 and its contribution to human disease R Van, A Cuevas-Navarro, P Castel, F McCormick Biochemical Journal 477 (15), 2755-2770, 2020 | 14 | 2020 |
| RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy A Cuevas-Navarro, M Wagner, R Van, M Swain, S Mo, J Columbus, ... Science Advances 9 (28), eadf4766, 2023 | 8 | 2023 |
| Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy M Holderfield, BJ Lee, J Jiang, A Tomlinson, KJ Seamon, A Mira, ... Nature, 1-8, 2024 | 3 | 2024 |
| Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy M Singh, M Holderfield, B Lee, J Jiang, A Tomlinson, K Seamon, A Mira, ... | 2 | 2023 |
| A novel mouse model reveals potential therapeutic strategies for RIT1-driven lung adenocarcinomas AM Mozzarelli, A Cuevas-Navarro, A Urisman, P Castel Cancer Research 84 (6_Supplement), 3938-3938, 2024 | | 2024 |
| Deciphering the mechanism of mitotic regulation and MAPK hyperactivation by RIT1 oncoproteins A Cuevas Navarro UCSF, 2022 | | 2022 |
| Impaired RAS Proteolysis Drives Clonal Hematopoietic Transformation S Chen, RS Vedula, P Castel, AC Navarro, SJ Hogg, E Wang, X Mi, ... Blood 138, 356, 2021 | | 2021 |
